Basenese Lou's Form 4 filing
ENDRA Life Sciences Inc. (NDRA) · filed Aug 27, 2021
- Accession no.
- 0001209191-21-053613
- Filed
- Aug 27, 2021
- Trade date
- Aug 25-26, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $91.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Basenese LouCIK 0001809482 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2021 | Common Stock | SSaleDisposed | −45,000 | $1.83F1 | −$82,350 | 54,068 | Direct | |
| Aug 26, 2021 | Common Stock | SSaleDisposed | −5,000 | $1.85 | −$9,250 | 49,068 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.81 to $1.84, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.